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Abstract After several years of research, HE4 was found to
be characterized by slightly worse sensitivity but significantly
higher specificity as compared with CA125. Further studies
led to the diagnostic potential of both markers (CA125 and
HE4) being combined in a single risk of malignancy algorithm
(ROMA) algorithm. The objective of this study was to assess
the diagnostic capabilities of the ROMA algorithm using age
ranges instead of dichotomization of patients according to the
pre- and postmenopausal status. A total of 413 female patients
were included in the study, including 162 premenopausal and
251 postmenopausal women. Calculation of the final ROMA
values was achieved by means of stepwise reduction of coef-
ficients in the proposed formula of: %ROMA=exp(PI)/[1-
exp(PI)]*100) and PI=A+W(HE4)*ln(HE4)+W(CA125)*ln
(CA125) and the arrangement of values with consideration to
the age group, HE4 level, differentiation of modification, and
directional coefficients as well as determination of individual
deviations affecting the widening of the median. The cutoff
value of modified algorithm ROMA P for the entire study
population was calculated from receiver operating character-
istic (ROC) curve and DeLongmethod at the levels of 23.5 %.
Marked higher sensitivity and negative predictive value
(NPV) values are observed for the standard ROMA algorithm
while higher specificity and positive predictive value (PPV)
values are observed for the modified algorithm ROMA P. The
proposed age-related modification of algorithm calculation
does not require the patients being dichotomized according
to their pre- or postmenopausal status, and satisfactory diag-
nostic values may be obtained using a single cutoff point for
the entire population.
Keywords HE4 . CA125 . ROMA algorithm . Ovarian
cancer . Diagnosis
Introduction
Ovarian cancer is responsible for the largest number of deaths
due to gynecological cancers in European and North American
women.Worldwide, it is second only to cervical cancer. Annual
incidence of ovarian cancer is estimated at more than 200,000
cases while the mortality is estimated at over 150,000 of deaths
[1]. Currently, we have no sufficient capabilities to perform
ovarian cancer screening examinations in the entire population
of women. The partial screening program includes high-risk
patients with BRCA 1 or BRCA 2 gene mutations [2]. There-
fore, the main stress is placed on the possibilities of earlier
diagnostics and identification of ovarian cancer at earlier stages
of the disease. Clinical staging remains one of the most impor-
tant prognostic factors that impact the survival parameters in
patients [3]. The first marker used in routine diagnostics of
ovarian cancer was the antigen CA125, widely used to date
[4]. In 2003, Hellstrom et al. [5] were the first to report the
potential use of HE4 as a marker in the diagnostics of ovarian
cancer. After several years of research, HE4 was found to be
characterized by slightly worse sensitivity but significantly
higher specificity as compared with CA125 [6–11]. Further
studies led to the diagnostic potential of both markers
(CA125 and HE4) being combined in a single risk of malig-
nancy algorithm (ROMA) [12–16]. According to numerous
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studies conducted to date, ROMA appears to be one of the best
methods for stratification of ovarian tumor patients into groups
of high vs. low risk of ovarian cancer. The algorithm is objec-
tive, easy to perform, inexpensive, and characterized by appro-
priate sensitivity and specificity [12, 13]. However, the search
for methods for achieving better results in terms of the algo-
rithm’s sensitivity and specificity is ongoing [17, 18].
The objective of this study was to assess the diagnostic
capabilities of the ROMA algorithm using age ranges instead




A total of 413 female patients were included in the study,
including 162 premenopausal and 251 postmenopausal wom-
en. Patients were diagnosed and treated at the Department of
Gynecological Surgery and Gynecological Oncology Adults
and Adolescents in Szczecin, Poland, between 2011 and 2015.
Qualified for the study were the consecutive patients who
attend the hospital presenting with ovarian tumor, ovarian
cyst, or ascites (suspected ovarian cancer). After informed
consent was obtained, blood samples were collected simulta-
neously and serum levels of HE4 and CA125were determined
on current basis without freezing at the hospital’s Central Lab-
oratory. All the samples were taken before diagnosis, not in
the follow-up period. Both markers are routinely determined
in all patients reporting to our clinic with adnexal lesions.
ROMA algorithm analyses based on specific age groups were
performed in a retrospective manner after an appropriate for-
mula was determined. In the clinical decision-making process,
each marker was analyzed separately. After histopathological
examination results were obtained, patients were finally qual-
ified into one of the two groups:
A. Patients with ovarian cancer
B. Patients with benign adnexal lesions
Patients with history of chronic renal diseases, history of
chronic lung diseases, metastatic ovarian tumors, ongoing
treatment of other cancers, or presenting with elevated creat-
inine levels were not qualified to the study. A detailed division
of patients in both groups is presented in Table 1.
Median values and ranges were determined for both groups
and all respective subgroups, with appropriate comparisons be-
ing made with respect to the levels of HE4 and CA125, ROMA
algorithm calculated in the standard manner (ROMA) as well
as the modified ROMA algorithm (ROMA P). Sensitivity,
specificity, as well as positive and negative predictive values
of CA125 and HE4 were determined for the standard and the
modified algorithm. Additionally, diagnostic usefulness of each
marker was determined using ROC-AUC.
Calculation of the final ROMAvalues was achieved bymeans
of stepwise reduction of coefficients in the proposed formula of:
%ROMA=exp(PI)/[1-exp(PI)]*100,
PI=A+W(HE4)*ln(HE4)+W(CA125)*ln (CA125),
Below 20 years old: A = −12; W(HE4) = 2.38;
W(CA125)=0.063,
From 21 to 30 years old: A=−11.44; W(HE4) = 2.19;
W(CA125)=0.158,
From 31 to 40 years old: A = −10.88; W(HE4) = 2;
W(CA125)=0.254,
From 41 to 50 years old: A=−10.32; W(HE4) = 1.81;
W(CA125)=0.349,
From 51 to 60 years old: A=−9.77; W(HE4) = 1.61;
W(CA125)=0.445,
From 61 to 70 years old: A=−9.21; W(HE4) = 1.42;
W(CA125)=0.541,
From 71 to 80 years old: A=−8.65; W(HE4) = 1.23;
W(CA125)=0.636,
Above 80 years old: A = −8.09; W(HE4) = 1.04;
W(CA125)=0.732.
In the calculation,we used also the arrangement of valueswith
consideration to the age group, HE4 level, differentiation ofmod-
ification and directional coefficients, as well as determination of
individual deviations affecting the widening of the median.
Laboratory methods
The HE4 serum levels of the marker were determined using
the Roche Elecsys® assay on a Cobas e601 apparatus. This is a
one-step sandwich electro-chemiluminescence immunoassay
(ECLIA) for quantitative determination of human epididymal
protein 4. The detection range for HE4 was 15–1500 pmol/l;
in case of values exceeding 1500 pmol/l, the samples were
diluted in a 1:20 ratio using Elecsys Diluent.
The CA125 serum levels of the marker were determined
using the ARCHITECT CA125 II assay on an ARCHITECT
2200SR System. This is a two-step immunoassay to determine
the presence of CA125 antigen using Chemiluminescent Mi-
croparticle Immunoassay (CMIA) technology.
CA125 and HE4 assays were carried out according to manu-
facturers’ instructions, with appropriate controls testingwithin the
normal ranges. The detection range for CA125 was 1–35 U/ml.
Statistical analysis
Descriptive characteristics of the examined population of patients
were prepared, including the minimum, maximum, mean, and
median values. Also, the scatter diagrams of the empirical values
of markers were plotted for individual study groups. The mean/
8880 Tumor Biol. (2016) 37:8879–8887
median values in individual groups and subgroups were com-
pared using the nonparametric Mann–Whitney’s U test.
The contingency table was used in the assessment of diag-
nostic usefulness of CA125 and HE4 assays and ROMAvalues
and subsequent calculation of the following parameters:
Sensitivity=TP/TP+FN
Specificity=TN/FP+TN
Positive predictive value (PPV)=TP/TP+FP
Negative predictive value (NPV)=TN/FN+TN
The diagnostic performance was studied using receiver oper-
ating characteristic (ROC) curves based on continuous variables.
HE4, CA125, and ROMA represented diagnostic variables act-
ing as stimulants which increase the probability of ovarian can-
cer proportionally to their rising value. The area under curve
(AUC), standard error (SEAUC), and confidence interval (CIAUC)
values for AUC were calculated according to the nonparametric
method of DeLong. We used this method to compare AUCs
considering the fact that measurements of HE4, CA125, and
ROMA were done for the same objects (groups of patients).
The level of significance was taken as p<0.05.
Results
Patient, biomarker, and algorithm baseline characteristics
Detailed characteristics of patients are presented in Table 1.
The analysis included a total of 162 patients with ovarian
cancer. As much as 81.5 % of these cancers were serous and
64.7 % of serous was of a high clinical stage. The group of
benign gynecological disorders consisted of 251 patients,
47.8 % of those being diagnosed with endometriosis. Also
presented in Table 1 is the distribution of patients into individ-
ual age groups used for modification of the ROMA algorithm.
Medians and ranges or marker levels as well as values
obtained using the standard and the modified ROMA algo-
rithm are presented in Table 2. Comparative analysis between
the values from the standard and the modified algorithm re-
vealed no statistically significant differences within the ana-
lyzed groups and subgroups. The only clearly evident differ-
ence was related to benign disorders being pooled regardless
of histopathological type, where the values obtained using the
modified algorithm were significantly higher (6.7 vs. 8.29 %,
p=0.0001).
ROC curve analysis
ROC curves were determined for CA125, HE4, ROMA, and
ROMA P in the entire study population, in the premenopausal
group, in the postmenopausal group, as well as in the groups
of high- and low-stage ovarian tumors (Table 3; Fig. 1). In
every case, each of the markers as well as both algorithms met
the criteria of good diagnostic tests with AUC values calcu-
lated for ROC curves being above 0.5. The modified algo-
rithm ROMA P is significantly better than CA125 in the ad-
vanced cancer group (AUC=0.994 vs. 0.969) and better than
HE4 in all cases except for the advanced cancer group. When
comparing the standard ROMA algorithm and the modified
ROMA P algorithm, superiority of standard algorithm was
observed in the group of postmenopausal patients
ROC curves were also determined within the analyzed age
ranges (Table 4). Similarly, also in this case, all analyzed pa-
rameters met the criteria of very good diagnostic tests in all
age groups. There were no significant differences between the







Median 59.7 (24–90) 35 (18–88)
Range
Hormonal status
Premenopausal 38 (23.5) 214 (85.3)
Postmenopausal 124 (76.5) 37 (14.7)
Age interval
W1 ( <20 YO) – 38 (15.1)
W2 (21–30) 3 (1.9) 55 (21.9)
W3 (31–40) 7 (4.3) 73 (29.1)
W4 (41–50) 28 (17.3) 48 (19.1)
W5 (51–60) 47 (29) 22 (8.8)
W6 (61–70) 43 (26.5) 10 (4)
W7 (71–80) 25 (15.4) 4 (1.6)
W8 (>81) 9 (5.6) 1 (0.4)
Ovarian cancer histopathology NA
Serous 132 (81.5) NA
Mucinous 9 (5.6) NA
Clear cell 8 (4.9) NA
Endometrioid 13 (8) NA
Oarian cancer FIGO stage NA
Stages I and II 54 (33.3) NA
Stages III and IV 105 (64.7) NA
Ovarian cancer grade NA
Grade 1 34 (21) NA
Grade 2 54 (33.3) NA
Grade 3 74 (45.7) NA
Benign tumor histopathology
Endometriosis NA 120 (47.8)
Teratoma NA 43 (17.1)
Follicular cysts NA 33 (13.1)
Paraovarian cysts NA 26 (10.4)
Hemorrhagic cysts NA 28 (11.6)
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modified algorithm ROMA P and CA125, HE4, and the stan-
dard ROMA algorithm. A trend towards higher AUS values
and thus towards a better diagnostic value was observed with
the increasing patients’ age.
Sensitivity, specificity, PPV, and NPV
The cutoff value ofmodified algorithmROMAP for the entire
study population was calculated from receiver operating char-
acteristic (ROC) curve and DeLong method at the levels of
23.5 %. The cutoff value of standard algorithm ROMA was
calculated based on the same statistical method at the levels of
14.1 % for the premenopausal and 25% for postmenopausal
women. The sensitivity, specificity, positive predictive value
and negative predictive value were calculated on the basis of
contingency tables, see Table 5. The difference between the
compared algorithms is evident. Marked higher sensitivity
and NPV values are observed for the standard ROMA algo-
rithm while higher specificity and PPV values are observed
for the modified algorithm ROMA P.
Discussion
In 2008, Moore et al. [12] determined that of all known bio-
markers within the panel used for diagnosing ovarian cancer,
HE4 was characterized by the highest sensitivity and
specificity. Numerous studies demonstrated a significant
Table 2 Serum CA125, HE4, ROMA, and ROMA P levels according to age, histology, FIGO stage, and tumor grade
CA125 (U/ml) HE4 (pmol/l) ROMA (%) ROMA P (%) p (ROMA vs. ROMA P)
Median Range Median Range Median Range Median Range
Ovarian cancer (all) 397.5 9–7459.1 340.7 12–9264 90.3 0.5–100 91.46 1.33–99.9 0.8641
Serous 421.1 9–7459.1 390.7 15–9264 91.9 0.5–100 92.5 1.3–99.9 0.7963
Mucinous 58.8 11.3–600 69.2 15–538 30.1 6.2–95.8 27.2 1.9–96.1 0.9699
Clear cell 389.9 95.8–1725.5 184.8 49.5–849.9 81.5 8.1–98.2 73.7 15.6–98.3 0.9581
Endometrioid 00 41.5–2996.8 340.7 46.1–1235 94.6 21–99.3 93.2 2.5–99.4 0.9591
FIGO stages I and II 130.3 9–2347 79 15–1235 35.3 0.5–99.3 33.6 1.3–99.3 0.8610
FIGO stages III and IV 591 18–7459.1 593.75 20.7–9264 96.8 9–100 97.1 10.1–99.9 0.6691
Grade 1 68.2 9–459.7 70.8 15–414.3 20.5 0.5–93.9 23.1 1.3–93.8 0.9087
Grade 2 420.1 14–7459.1 289.3 20.7–9264 88.5 8.4–100 88.9 10.1–99.9 0.0114
Grade 3 535.1 11.2–5109.8 569.8 20.4–8160 96.7 1–100 96.4 2.98–99.9 0.8963
Benign diseases (all) 22.5 3.2–502.7 46.7 17.8–206.5 6.7 0.7–87 8.29 1.15–85.2 0.0001
Endometriosis 45.5 6.7–377 45.2 17.8–86.7 6.6 0.7–35.34 9.1 1.2–26.16 0.2295
Teratoma tumors 15.5 6.3–51.9 46.6 26.3–724 6.48 1.65–17.9 6.76 1.87–17.6 0.2835
Follicular cysts 14.5 3.2–88 55.3 24.2–206.5 8.76 1.6–65.7 9.9 1.6–67.8 0.4886
Paraovarian cysts 13.7 4.1–52.7 48.6 36.4–186.8 7.5 3.7–87 7.9 3.8–85.2 0.7075
Hemorrhagic cysts 15.4 5.5–274.8 44.3 24.8–95.7 5.7 1.7–31.6 6.5 3.2–30.9 0.6522
AGE interval
W1 ovarian cancer group – – – – – – – – –
W2 ovarian cancer group 55.2 27–135.1 45.4 44.1–103.9 6.2 6–35 7.5 7.1–37.7 0.3827
W3 ovarian cancer group 403.6 98.1–1252 95.4 15–464.8 31.5 0.5–95.5 43.6 1.3–95.6 0.3619
W4 ovarian cancer group 265.4 14–4638.8 92.9 15–1500 34.7 0.5–99.7 44.7 1.3–99.4 0.7743
W5 ovarian cancer group 500 9–5887 439.3 12–1655 96.4 4.5–99.7 96.3 1.9–99.8 0.7883
W6 ovarian cancer group 233.3 9.8–7459.1 334.5 22–9264 90.9 6–100 91.6 5.2–99.9 0.9786
W7 ovarian cancer group 839 21–5659 658.4 37–8160 97 25–100 97.2 23.8–99.9 0.7710
W8 ovarian cancer group 777.5 66.9–3724 871.2 85.8–4940 97.7 55.1–100 97.9 55.1–99.9 1.0000
W1 benign group 16 4.1–274.8 41.5 24.2–84.7 6.2 1.56–22.1 6.4 1.56–22.1 0.9420
W2 benign group 28.1 7.7–377 45.5 26.3–80.4 5.4 1.65–20.3 6.2 1.87–22.7 0.0913
W3 benign group 32.3 7.1–191.5 47.3 31.7–86.7 7 2.6–24.1 9.2 3.2–26.2 0.9529
W4 benign group 21.6 5.5–168.8 44.5 17.8–74.2 6 0.7–17.6 8.9 1.15–21.3 0.0079
W5 benign group 12.4 3.2–82.1 48.5 27.5–85.1 6.9 1.8–35.3 8.4 4.4–23.4 0.6641
W6 benign group 15.9 6.7–79.8 63.8 47.1–206.5 14.3 6.7–65.7 14.1 6.6–67.8 0.6232
W7 benign group 9.55 6.3–52.7 69.5 52–186 9.7 7.3–87 9.7 7.6–85.2 1.0000
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improvement in the sensitivity and specificity of prediction of
pathological changes within the adnexes when using CA125
and HE4 together instead of as separate markers [12, 19–22].
The sensitivity of CA125, when analyzed together with HE4,
increases from 43 to 76.4 % [12]. Therefore, in 2009, Moore
et al. [23] described the first predictive model for estimation of
the risk of malignant epithelial ovarian cancer in women with
pathological lesions within the pelvic region. In 2011, on the
basis of the research of the same authors [24], the Food and
Drug Administration approved the algorithm for clinical use.
A continuous increase in the number of published studies on
the application of ROMA in clinical practice has been ob-
served ever since [25–29]. In 2012, during an experts’ meet-
ing inWiesbaden, the efficacy of ROMAwas confirmed. Pos-
sibilities for improving the algorithm’s diagnostic abilities
were also considered by including additional analysis of pa-
tients’ age, smoking status, renal insufficiency-related condi-
tions, or acute cardiac insufficiency-related conditions [17].
It seems the most important factor affecting HE4 levels and
thus the ROMA algorithm values is the age of the patients
[3–33]. In the study by Bolstadt et al. [32], conducted in a
European population, HE4 level as compared with that in
women at the age of 20 was found to be increased by 2 % in
women at the age of 30, 9 % in women at the age of 40, 20 % in
women at the age of 50, 37 % in women at the age of 60, 63 %
in women at the age of 70, and as much as 101 % in women at
the age of 80. The authors suggest that HE4 levels should be
analyzed in caution in patients after the age of 70. Moore et al.
[31] observed the following HE4 level changes correlated with
patients’ age: median level was 46.2 pmol/l before the age of 30,
43.5 pmol/L at the age of 30–39, 50.5 pmol/l after the age of 40
and before menopause, 50.7 pmol/l before the age of 60 and
after menopause, 59.8 pmol/l at the age of 60–69, 66.9 pmol/l at
the age of 70–79, and as much as 113.4 pmol/l after the age of
80. In our study population, HE4 levels were also found to
increase with age, albeit to a smaller degree than reported by
Bolstad [33] and Moore [31]. In our analysis, the increase in
HE4 levels after the age of 60 as compared with the value at the
age of below 20 was about 40 %. Of course, this may be due to
the differences in analytical tests as Bolstad et al. [33] andMoore
et al. [31] used laboratory tests from Fujirebio while our study
was conducted using laboratory tests from Roche. ROMA
values (modified ROMAvalues) were calculated using stepwise
reduction of coefficients while taking into account the different
Table 3 Values and comparisons
of ROC-AUC for ROMA,
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Fig. 1 ROC curves of the
standard ROMA algorithm and
the ROMA P (algorithm
calculated in the age ranges)
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age groups and differentiation of modification and directional
coefficients in the ROMA algorithm calculation formula. AUC
values determined for the modified algorithm ROMA P meet
the criteria of a very good diagnostic test in every analysis (all
ovarian cancer patients: AUC=0.923; advanced ovarian cancer
patients: AUC=0.994; early-stage ovarian cancer patients:
AUC=0.794; premenopausal women: AUC=0.829; and post-
menopausal women: AUC=0.935). No significant differences
were observed when comparing AUC values between the stan-
dard and the modified method of algorithm calculation. How-
ever, clinically significant differences were observed when com-
paring specificity, PPV, and NPV. ROMA algorithm calculated
according to the standard formula was characterized by better
sensitivity and positive prediction values. However, the age-
adjusted algorithm ROMA P proved significantly superior in
terms of sensitivity and negative predictive values with only a
minor reduction in sensitivity in premenopausal women only.
The results in premenopausal womenwere as follows: sensitivity
64.9 %, specificity 99.1 %, PPV 92.3 %, and NPV 94.2. Results
in postmenopausal women were 91.1, 91.9, 97.4, and 75.6 %,
respectively. Comparedwith the results obtained by other authors
who analyzed the ROMA algorithm using the standard criteria,
the obtained results are very good. In their studies, Moore et al.
[24] obtained the sensitivity of 88.1 %, specificity of 74.2 %,
PPVof 17.8%, and NPVof 98.3 NPVin premenopausal women
compared with 90.2, 76, 56.1, and 95.8 % in postmenopausal
Table 4 Values and
comparisons of ROC-
AUC for ROMA,
ROMA P, CA125, and









ROMA P vs. CA125
p value
ROMA P vs. HE4
p value
ROMA P vs. ROMA
p value
























Table 5 Sensitivity, specificity, PPV, and NPVof ROMA and ROMA P
Ovarian cancer vs. benign ovarian diseases Sensitivity (%) Specificity (%) PPV (%) NPV(%)
All PM M All PM M All PM M All PM M
ROMA 88.1 75.7 91.9 84.9 92.5 89.2 87.6 63.6 96.6 92.4 95.7 76.7
ROMA P 85 64.9 91.1 98 99.1 91.9 96.5 92.3 97.4 84.8 94.2 75.6
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women, respectively. Molina et al. [27] obtained analogous re-
sults in premenopausal women: 74.1, 88.9, 44.4, and 96.6 % as
well as in postmenopausal women: 95.2, 83.1, 88.9, and 92.5 %.
To date, the only paper that included stratification of patients
on the basis of HE4, CA125, and patient age was published
several months ago [34]. It relates to a large, multicenter study
in which 2665 at 8 centers were analyzed on the basis of the
Copenhagen Index (CPH-I). Assuming that the cutoff value for
CPH-I is at the level of 0.07, sensitivity and specificity values of
95 and 78.4 % were obtained, respectively.
Conclusion
It appears that further studies on the improvement of diagnostic
criteria of CA125- andHE4-based algorithm consisting in elim-
ination of the impact of factors potentially affecting the values
of both markers and thus of the algorithm itself, is a legitimate
trend. As shown by the results of our analysis, the proposed
age-related modification of algorithm calculation does not re-
quire the patients being dichotomized according to their pre- or
postmenopausal status and satisfactory diagnostic values may
be obtained using a single cutoff point for the entire population.
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